Serum Mediators in Patients with Both Type 2 Diabetes Mellitus and Pruritus

Authors

  • Guan-Yi He Department of Dermatology, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan https://orcid.org/0000-0001-7096-8891
  • Tai-Yi Hsu 4School of Medicine, College of Medicine, China Medical University, Taichung City, Taiwan; Department of Emergency Medicine, China Medical University Hospital, Taichung City, Taiwan; Department of Public Health, China Medical University, Taichung City, Taiwan https://orcid.org/0000-0003-3095-1248
  • Ching-Wen Chen Subdivision of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
  • Feng-Jung Nien Department of General Medicine, National Taiwan University Cancer Center, Taipei City, Taiwan
  • Huan-Yuan Chen Institute of Biomedical Sciences, Academia Sinica, Taipei City, Taiwan https://orcid.org/0000-0002-6390-1178
  • Chia-Yu Chu Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan https://orcid.org/0000-0002-9370-3279
  • Li-Fang Wang Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 8, Zhongshan S. Road, Zhongzheng District, Taipei City 100226, Taiwan https://orcid.org/0000-0002-1709-9401

DOI:

https://doi.org/10.2340/actadv.v103.4863

Keywords:

chemokine CXCL10, diabetes mellitus, granulocyte-macrophage colony-stimulating factor;, interferon-inducible protein 10, pruritus

Abstract

Chronic pruritus is an unpleasant sensory perception that negatively affects quality of life and is common among patients with type 2 diabetes mellitus. Current antipruritic therapies are insufficiently effective. Thus, the mediation of diabetic pruritus by histamine-independent pathways is likely. The aim of this study was to identify possible mediators responsible for diabetic pruritus. A total of 87 patients with type 2 diabetes mellitus were analysed, of whom 59 had pruritus and 28 did not. The 2 groups were assessed for baseline demographics, serum biochemistry parameters, cytokines, and chemokines. This study also investigated the associations of these factors with the severity of itching. Neither haemoglobin A1c nor serum creatinine levels were correlated with severity of itching. Significantly higher levels of interleukin-4 (p = 0.004), interleukin-13 (p = 0.006), granulocyte-macrophage colony-stimulating factor (p < 0.001) and C-X-C motif chemokine ligand 10 (p = 0.028) were observed in the patients with pruritus than in those without pruritus. Moreover, the levels of these mediators were positively correlated with the severity of itching. Thus, novel antipruritic drugs can be developed to target these molecules. This is the first study to compare inflammatory mediators comprehensively in patients with diabetes mellitus with pruritus vs those without pruritus. 

Downloads

Download data is not yet available.

References

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health 2020; 10: 107-111.

https://doi.org/10.2991/jegh.k.191028.001 DOI: https://doi.org/10.2991/jegh.k.191028.001

Lima AL, Illing T, Schliemann S, Elsner P. Cutaneous manifestations of diabetes mellitus: a review. Am J Clin Dermatol 2017; 18: 541-553.

https://doi.org/10.1007/s40257-017-0275-z DOI: https://doi.org/10.1007/s40257-017-0275-z

Stefaniak AA, Krajewski PK, Bednarska-Chabowska D, Bolanowski M, Mazur G, Szepietowski JC. Itch in adult population with type 2 diabetes mellitus: clinical profile, pathogenesis and disease-related burden in a cross-sectional study. Biology (Basel) 2021; 10: 1332.

https://doi.org/10.3390/biology10121332 DOI: https://doi.org/10.3390/biology10121332

Stefaniak A, Chlebicka I, Szepietowski J. Itch in diabetes: a common underestimated problem. Adv Dermatol Allergol/Postępy Dermatologii i Alergologii 2019; 38: 177-183.

https://doi.org/10.5114/ada.2019.89712 DOI: https://doi.org/10.5114/ada.2019.89712

Teoh Y, Yeo B, Koh M, Teo R. Pruritus in the elderly and its impact on quality of life. J Am Acad Dermatol 2012; 66: AB11.

https://doi.org/10.1016/j.jaad.2011.11.057 DOI: https://doi.org/10.1016/j.jaad.2011.11.057

Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Giménez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol 2019; 99: 469-506.

https://doi.org/10.2340/00015555-3164 DOI: https://doi.org/10.2340/00015555-3164

Ko MJ, Chiu HC, Jee SH, Hu FC, Tseng CH. Postprandial blood glucose is associated with generalized pruritus in patients with type 2 diabetes. Eur J Dermatol 2013; 23: 688-693.

https://doi.org/10.1684/ejd.2013.2100 DOI: https://doi.org/10.1684/ejd.2013.2100

Yang QP, Chen YY, Li Z, Xu M. Major risk factors analysis of pruritus complicated by type 2 diabetes mellitus and the effect of comprehensive nursing intervention. Front Surg 2022; 9: 842884.

https://doi.org/10.3389/fsurg.2022.842884 DOI: https://doi.org/10.3389/fsurg.2022.842884

Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity 2020; 52: 753-766.

https://doi.org/10.1016/j.immuni.2020.04.008 DOI: https://doi.org/10.1016/j.immuni.2020.04.008

Mahlangu T, Dludla PV, Nyambuya TM, Mxinwa V, Mazibuko-Mbeje SE, Cirilli I, et al. A systematic review on the functional role of Th1/Th2 cytokines in type 2 diabetes and related metabolic complications. Cytokine 2020; 126: 154892.

https://doi.org/10.1016/j.cyto.2019.154892 DOI: https://doi.org/10.1016/j.cyto.2019.154892

Reich A, Chatzigeorkidis E, Zeidler C, Osada N, Furue M, Takamori K, et al. Tailoring the cut-off values of the visual analogue scale and numeric rating scale in itch assessment. Acta Derm Venereol 2017; 97: 759-760.

https://doi.org/10.2340/00015555-2642 DOI: https://doi.org/10.2340/00015555-2642

Reich A, Bożek A, Janiszewska K, Szepietowski JC. 12-item pruritus severity scale: development and validation of new itch severity questionnaire. Biomed Res Int 2017; 2017: 3896423.

https://doi.org/10.1155/2017/3896423 DOI: https://doi.org/10.1155/2017/3896423

Chen YY, Yang QP, Peng SP, Li ZZ, Yang HY, Fan XG, et al. Risk factors and psychological condition of pruritus in type 2 diabetes mellitus: a retrospective, propensity score-matched study. Eur Rev Med Pharmacol Sci 2022; 26: 5353-5361.

Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta 2014; 1843: 2563-2582.

https://doi.org/10.1016/j.bbamcr.2014.05.014 DOI: https://doi.org/10.1016/j.bbamcr.2014.05.014

Storan ER, O'Gorman SM, McDonald ID, Steinhoff M. Role of cytokines and chemokines in itch. Handb Exp Pharmacol 2015; 226: 163-176.

https://doi.org/10.1007/978-3-662-44605-8_9 DOI: https://doi.org/10.1007/978-3-662-44605-8_9

Shibuya R, Takimoto-Ito R, Kambe N, Kabashima K. A new era with the development of cytokine-based therapy for pruritus. J Invest Dermatol 2022; 142: 47-52.

https://doi.org/10.1016/j.jid.2021.09.023 DOI: https://doi.org/10.1016/j.jid.2021.09.023

Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013; 2013: 976810.

https://doi.org/10.1155/2013/976810 DOI: https://doi.org/10.1155/2013/976810

Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 2018; 73: 29-36.

https://doi.org/10.1111/all.13239 DOI: https://doi.org/10.1111/all.13239

Ko MJ, Peng YS, Chen HY, Hsu SP, Pai MF, Yang JY, et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol 2014; 71: 1151-1159.e1151.

https://doi.org/10.1016/j.jaad.2014.08.004 DOI: https://doi.org/10.1016/j.jaad.2014.08.004

Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 2021; 30: 804-810.

https://doi.org/10.1111/exd.14279 DOI: https://doi.org/10.1111/exd.14279

Oweis AO, Al-Qarqaz F, Bodoor K, Heis L, Alfaqih MA, Almomani R, et al. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. Cytokine 2021; 138: 155369.

https://doi.org/10.1016/j.cyto.2020.155369 DOI: https://doi.org/10.1016/j.cyto.2020.155369

Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78: S28-s36.

https://doi.org/10.1016/j.jaad.2017.12.022 DOI: https://doi.org/10.1016/j.jaad.2017.12.022

Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat 2022; 33: 1547-1553.

https://doi.org/10.1080/09546634.2020.1853024 DOI: https://doi.org/10.1080/09546634.2020.1853024

Le Floc'h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy 2020; 75: 1188-1204.

https://doi.org/10.1111/all.14151 DOI: https://doi.org/10.1111/all.14151

Fallahzadeh MK, Roozbeh J, Geramizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant 2011; 26: 3338-3344.

https://doi.org/10.1093/ndt/gfr053 DOI: https://doi.org/10.1093/ndt/gfr053

Hon KL, Tsang KY, Kung JS, Leung TF, Lam CW, Wong CK. Clinical signs, staphylococcus and atopic eczema-related seromarkers. Molecules 2017; 22: 291.

https://doi.org/10.3390/molecules22020291 DOI: https://doi.org/10.3390/molecules22020291

Surendar J, Mohan V, Pavankumar N, Babu S, Aravindhan V. Increased levels of serum granulocyte-macrophage colony-stimulating factor is associated with activated peripheral dendritic cells in type 2 diabetes subjects (CURES-99). Diabetes Technol Ther 2012; 14: 344-349.

https://doi.org/10.1089/dia.2011.0182 DOI: https://doi.org/10.1089/dia.2011.0182

Pastore S, Fanales-Belasio E, Albanesi C, Chinni LM, Giannetti A, Girolomoni G. Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. J Clin Invest 1997; 99: 3009-3017.

https://doi.org/10.1172/JCI119496 DOI: https://doi.org/10.1172/JCI119496

Chen Q, Zhong H, Chen WC, Zhai Z, Zhou Z, Song Z, et al. Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2018; 32: 441-448.

https://doi.org/10.1111/jdv.14541 DOI: https://doi.org/10.1111/jdv.14541

Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.

https://doi.org/10.1056/NEJM199802123380706 DOI: https://doi.org/10.1056/NEJM199802123380706

Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 2013; 36: 364-371.

https://doi.org/10.1007/s10753-012-9555-1 DOI: https://doi.org/10.1007/s10753-012-9555-1

Tokuriki A, Seo N, Ito T, Kumakiri M, Takigawa M, Tokura Y. Dominant expression of CXCR3 is associated with induced expression of IP-10 at hapten-challenged sites of murine contact hypersensitivity: a possible role for interferon-gamma-producing CD8(+) T cells in IP-10 expression. J Dermatol Sci 2002; 28: 234-241.

https://doi.org/10.1016/S0923-1811(01)00172-4 DOI: https://doi.org/10.1016/S0923-1811(01)00172-4

Jinquan T, Jing C, Jacobi HH, Reimert CM, Millner A, Quan S, et al. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol 2000; 165: 1548-1556.

https://doi.org/10.4049/jimmunol.165.3.1548 DOI: https://doi.org/10.4049/jimmunol.165.3.1548

Nelson TE, Gruol DL. The chemokine CXCL10 modulates excitatory activity and intracellular calcium signaling in cultured hippocampal neurons. J Neuroimmunol 2004; 156: 74-87.

https://doi.org/10.1016/j.jneuroim.2004.07.009 DOI: https://doi.org/10.1016/j.jneuroim.2004.07.009

Qu L, Fu K, Yang J, Shimada SG, LaMotte RH. CXCR3 chemokine receptor signaling mediates itch in experimental allergic contact dermatitis. Pain 2015; 156: 1737-1746.

https://doi.org/10.1097/j.pain.0000000000000208 DOI: https://doi.org/10.1097/j.pain.0000000000000208

Walsh CM, Hill RZ, Schwendinger-Schreck J, Deguine J, Brock EC, Kucirek N, et al. Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis. Elife 2019; 8: e48448.

https://doi.org/10.7554/eLife.48448 DOI: https://doi.org/10.7554/eLife.48448

Klunker S, Trautmann A, Akdis M, Verhagen J, Schmid-Grendelmeier P, Blaser K, et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol 2003; 171: 1078-1084.

https://doi.org/10.4049/jimmunol.171.2.1078 DOI: https://doi.org/10.4049/jimmunol.171.2.1078

Xu H, Nakayama K, Ogawa S, Sugiura A, Kato T, Sato T, et al. [Elevated plasma concentration of IP-10 in patients with type 2 diabetes mellitus]. Nihon Jinzo Gakkai Shi 2005; 47: 524-530 (in Japanese).

Schulthess FT, Paroni F, Sauter NS, Shu L, Ribaux P, Haataja L, et al. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metab 2009; 9: 125-139.

https://doi.org/10.1016/j.cmet.2009.01.003 DOI: https://doi.org/10.1016/j.cmet.2009.01.003

Chang CC, Wu CL, Su WW, Shih KL, Tarng DC, Chou CT, et al. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep 2015; 5: 10096.

https://doi.org/10.1038/srep10096 DOI: https://doi.org/10.1038/srep10096

Additional Files

Published

2023-02-28

How to Cite

He, G.-Y., Hsu, T.-Y., Chen, C.-W. ., Nien, F.-J., Chen, H.-Y. ., Chu, C.-Y. ., & Wang, L.-F. . (2023). Serum Mediators in Patients with Both Type 2 Diabetes Mellitus and Pruritus. Acta Dermato-Venereologica, 103, adv00875. https://doi.org/10.2340/actadv.v103.4863